261
Participants
Start Date
October 10, 2000
Primary Completion Date
January 7, 2003
tiotropium bromide
St. Elizabeth's Medical Center of Boston, Boston
Mayo Clinic, Rochester
St. Thomas Health Services, Nashville
Presbyterian Hospital of Dallas, Dallas
Phase I Unit, Randwick
Immunology Department, Westmead
Department of Respiratory Medicine, Daw Park
The Queen Elizabeth Hospital, Woodville
Department of Respiratory Medicine, Heidelberg
Respiratory Research, Calgary
University of Alberta, Edmonton
Respiratory Clinic, Vancouver
Boehringer Ingelheim Investigational Site, Halifax
Cardio Repiratory, Hamilton
Kingston General Hospital, Kingston
1053 Carling Avenue, Ottawa
Department of Respiratory Medicine, Toronto
University Health Network - Toronto General Hospital, Toronto
Montreal Chest Institute - McGill University Health Centre, Montreal
Pulmonary Function Lab, Montreal
Hopital Laval, Ste-Foy
Boehringer Ingelheim Investigational Site, Saskatoon
Klinikum der Universität zu Köln, Cologne
Pneumologisches Forschungsinstitut GmbH am Krankenhaus, Hamburg
Fraunhofer-Institut für Toxikologie und, Hanover
Universitätsklinikum Schleswig-Holstein, Kiel
Neurologische Klinik der Otto-von-Guericke-Universität, Magdeburg
Boehringer Ingelheim Investigational Site, München
Lead Sponsor
Boehringer Ingelheim
INDUSTRY